Form 4: Amphastar Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold 500 shares of common stock at an average price of $24.0829 on May 1, 2025, under a pre-arranged trading plan.
Summary
- On May 1, 2025, Floyd F. Petersen, a director of Amphastar Pharmaceuticals, sold 500 shares of common stock.
- The sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
- The shares were sold at a weighted average price of $24.0829, with individual prices ranging from $23.785 to $24.325.
- Following the transaction, Petersen beneficially owns 73,409 shares of Amphastar Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to a stock sale by a company director under a pre-arranged trading plan, indicating a neutral sentiment.
Industry Context
Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 trading plan indicates that the sales were pre-planned and not based on insider information.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder confidence, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2024-11-26 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-05-01 | Date of stock sale transaction |
| 2025-05-02 | Date of Form 4 filing |
Keywords
Form 4, Amphastar Pharmaceuticals, Floyd F. Petersen, stock sale, Rule 10b5-1, director, AMPH
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.